Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 10Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Xanthogranuloma, Juvenile 1Lymphoma, Follicular 1IDH1-Mutated Malignancies 1Histiocytic Sarcoma 1Chondrosarcoma 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Biliary Tract Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

ivosidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
IDH1-Mutated Malignancies × ivosidenib × 90 days × Clear all
NCT07006688 2026-05-12

A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

Servier

Phase 1 Recruiting
30 enrolled

IDH1-Mutated Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡